



ORIGINAL

# [Translated article] Basal Cell Carcinoma: Incidence and Trends in Valencia, Spain

R. García Ruiz<sup>a,\*</sup>, A. Mateu Puchades<sup>a</sup>, V. Alegre de Miquel<sup>b</sup>

<sup>a</sup> Hospital Universitario Dr. Peset, Valencia, Spain

<sup>b</sup> Consorcio Hospital General Universitario de Valencia, Valencia, Spain

Received 5 January 2024; accepted 24 February 2024

## KEYWORDS

Basal cell carcinoma;  
Epidemiology;  
Incidence;  
Trends;  
Lifetime risk

## Abstract

**Background:** There is a need for epidemiological and incidence data on the occurrence of basal cell carcinoma (BCC) in Spain.

**Objectives:** Our study was designed to retrospectively retrieve cases from our computer databases from 2010 through 2016 to provide updated data on the actual incidence of BCC in Valencia, eastern Spain.

**Material and methods:** This was an epidemiological study on basal cell carcinoma conducted in Valencia, eastern Spain. We analyzed a total of 2171 patients and 4047 tumors, and gathered data to estimate the actual incidence of BCC in our region.

**Results and conclusions:** Our study confirmed that the incidence of BCC is much higher than previously reported. We calculated a crude incidence of 410.38 BCCs/100 000 person-years, an adjusted rate for the European population of 256.98 BCCs/100 000 person-years, and an adjusted rate for the world population of 196.26 BCCs/100 000 person-years. Risk is up to 29.49% higher for men (464.07 cases/100 000 person-years vs 358.40 cases/100 000 person-years for women). Incidence also increases by an annual 3.91% (a significantly higher annual incidence of 8.28% in women vs a 0.92% annual incidence in men). Overall, the lifetime risk for developing a BCC is 5.8% (5.02% in women and 7% in men).

© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

DOI of original article: <https://doi.org/10.1016/j.ad.2024.02.029>

\* Corresponding author.

E-mail address: [lucksyja@gmail.com](mailto:lucksyja@gmail.com) (R. García Ruiz).

<https://doi.org/10.1016/j.ad.2024.09.010>

0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: R. García Ruiz, A. Mateu Puchades and V. Alegre de Miquel, [Translated article] Basal Cell Carcinoma: Incidence and Trends in Valencia, Spain, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.09.010>

**PALABRAS CLAVE**

Carcinoma  
basocelular;  
Epidemiología;  
Incidencia;  
Tendencias;  
Riesgo vital

**Carcinoma basocelular: incidencia y tendencias en Valencia (España)**

**Resumen**

*Antecedentes:* Existe una necesidad de datos epidemiológicos e incidencia al respecto del carcinoma basocelular (CBC) en España (y en concreto en Valencia).

*Objetivos:* Para proporcionar datos más actualizados sobre la incidencia real del CBC en Valencia, al este de España, se diseñó un estudio para recuperar casos retrospectivamente de nuestras bases de datos informatizadas entre los años 2010 y 2016.

*Material y métodos:* Se analizaron 2171 pacientes con 4047 CBC de nuestras bases de datos informatizadas, y conjuntamente con los datos poblacionales obtenidos se consiguió hacer una estimación de la incidencia real de este tumor así como su tendencia temporal.

*Resultados y conclusiones:* Nuestro estudio confirma que la incidencia del CBC es mucho más alta de lo previamente reportado para nuestra área geográfica. Se calculó una incidencia bruta de 410,38 casos/100.000 hab/año, una incidencia ajustada por población europea de 256,98 casos/100.000 hab/año y una incidencia ajustada por población mundial de 196,26 casos/100.000 hab/año. El riesgo es un 29,49% superior para los hombres (464,07 casos/100.000 hab/año, frente a los 358,40 casos/100.000 hab/año en las mujeres). La incidencia está en aumento a una media del 3,91% por año (significativamente mayor para las mujeres: incrementando un 8,28% al año frente al 0,92% en hombres). El riesgo vital de desarrollar un CBC es del 5,8% globalmente, siendo del 5,02% para las mujeres y del 7% para los hombres.

© 2024 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

**Introduction**

Basal cell carcinoma (BCC) is the most common malignant neoplasm in humans, both among dermatological conditions and globally. It originates at the basal layer of the epidermis and appendages, which has an impact on its progression and clinical signs.

Although it is a tumor with a high incidence rate, elevated cure rate, and multiple therapeutic options, systematic records are scarce, making high-quality epidemiological studies challenging.

Former epidemiological studies conducted worldwide have found extremely variable incidences, ranging from < 1 case per 100,000 inhabitants per year in Kenya<sup>1</sup> to > 1500 cases per 100,000 inhabitants per year in Australia.<sup>2</sup>

In Spain, the incidence rate seems to be at an intermediate level, around 250 cases per 100,000 inhabitants per year.

There are few extensive studies on this topic in the literature, primarily 2 patient registries, one from Soria (1998 to 2000)<sup>3</sup> and the other one from Girona (1994 to 2007, later extended to 2012),<sup>4</sup> which lack data on individual tumors and second tumors (a relevant issue, as synchronous and metachronic tumor multiplicity of BCC has been demonstrated).<sup>5</sup> Both studies reported a crude incidence rate of nearly 150 cases per 100,000 inhabitants per year.

In a different study—methodologically more correct but covering only 1 year<sup>6</sup>—in the Barcelonés region, all BCC diagnoses were collected, yielding a more accurate estimate of 253.2 cases per 100,000 inhabitants per year.

It has been reported in studies worldwide—including the previously mentioned Girona study<sup>7</sup>—that the incidence rate of BCC is on the rise.

We conducted this retrospective study to provide updated and as accurate data as possible on the incidence of BCC in our region (Valencia).

**Materials and methods**

Our study population was assigned to the Department of Hospital Universitario Dr. Peset in Valencia, which covers approximately 20% of the population of Valencia and its metropolitan area (about 345,000 people).

The study design was submitted and approved by our hospital Ethics and Clinical Research Committee (June 30<sup>th</sup>, 2017, CEIC Code: 76/17).

Using the data extraction tools of computerized health records, we filtered all patients diagnosed with suspected basal cell carcinoma—including those from other specialties—treated in our health department (both in hospital consultations and in the outpatient specialty center affiliated with the same department and sharing the assigned population) from 2010 through 2016.

This time frame was selected because it included complete years when it was possible to analyze the health records when the project was presented to the CEIC.

This search yielded more than 30,000 entries of health records from a total of 7425 patients. Complete records of 3057 of these patients were reviewed and randomly selected due to the immense volume of data (41.17%) to find 2171 patients with a confirmed diagnosis. With this sample, the total number of patients is estimated at 5273.

Both histological and clinical-dermoscopic diagnoses were accepted as confirmed for dermatology records when no alternative diagnosis was present (15.59% of cases). This clinical criterion—although different from the exclusively histological approach used in other studies—is more rep-

representative of reality, as it has been demonstrated that, assisted by dermoscopy, dermatologists yield a diagnostic accuracy > 98% for this type of tumor.<sup>8</sup>

After reviewing the records, a total of 4047 BCCs were found during the study period, averaging 1.86 BCCs per person (with an estimated 9830 in the entire sample).

For sex analysis, according to current recommendations, the sex assigned at birth (based on external anatomy and chromosomal genotype) was considered the defining factor.

Accurate and updated population data from our health department were collected annually from the Valencian Institute of Statistics (IVE).<sup>9</sup> Table 1 shows a significant variation in the population covered by our department starting in 2015 due to a reorganization of areas conducted at the end of the previous year.

The characteristics of the population covered by our health department (in terms of age distribution, income, and other factors) are very similar to those of other departments in the Valencia metropolitan area, according to data provided by IVE, so it is reasonable to assume that the distribution is sufficiently homogeneous for the results to be applicable to the entire geographic area.

## Results

Knowing the estimated cases (quite precisely due to our high n) in our study area, the population assigned to our health department (which varies from year to year), and age distribution (which was practically constant throughout the period), we can calculate the crude incidence rate of basal cell carcinoma, the age-specific incidence rate, and the annual variation in incidence. All these data are collected in Table 1.

During the studied period, the mean crude incidence rate is 410.38 cases per 100,000 inhabitants per year, which is significantly higher than previously reported figures.

When analyzing by sex, the incidence in men is up to 29.49% higher, reaching 464.07 cases per 100,000 inhabitants per year, while for women it is only 358.40 cases per 100,000 inhabitants per year.

Moreover, the trend towards increasing incidence is clear, with a variation between the first and the last (7<sup>th</sup>) year of the study of 23.47%, and a mean annual increase estimated at 3.91%.

This increase is especially pronounced in women, with an annual rise of 8.28% vs only 0.92% in men.

To enhance the comparability of our results, mean population values for each age range were collected, as well as the incidence (also calculated separately by sex) and included in the corresponding table (Table 2) to standardize our rates with the European population<sup>10</sup>: 256.98 cases per 100,000 inhabitants per year; and with the global population<sup>11</sup>: 196.26 cases per 100,000 inhabitants per year.

As seen in the age-specific incidence columns in Table 2, the risk of developing a BCC is higher for women up to age 60. After that, the risk in men increases significantly, doubling that of women from age 75 onwards.

According to our data, up to 42% of patients will have, at least, a second BCC. Overall, the mean count is 1.86 BCCs per patient, higher for men (2.13 BCCs/patient) vs women (1.6 BCCs/patient).

Table 1 Incidence rates of basal cell carcinoma and trends.

Year	Population			BCC in sample			BCC in population (estimate)			Incidence (BCC/100,000 inhabitants per year)			Variation		
	Women	Men	Total	Women	Men	Total	Women	Men	Total	Women	Men	Total	Women	Men	Total
2010	192,672	186,553	379,225	224	327	551	544.06	794.23	1338.30	282.38	425.74	352.90	-	-	-
2011	193,194	187,058	380,252	249	360	609	604.78	874.39	1479.17	313.05	467.44	389.00	+10.86	+9.79	+10.23
2012	188,259	182,281	370,540	218	344	562	529.49	835.53	1365.01	281.26	458.37	368.39	-10.15	-1.94	-5.30
2013	187,712	181,750	369,462	297	324	621	721.37	786.95	1508.32	384.30	432.98	408.25	+36.64	-5.54	+10.82
2014	185,088	179,211	364,299	294	376	670	714.08	913.25	1627.33	385.81	509.59	446.70	+0.39	+17.69	+9.42
2015	141,005	136,528	277,533	255	284	539	619.36	689.79	1309.15	439.24	505.24	471.71	+13.85	-0.85	+5.60
2016	140,188	135,736	275,924	244	251	495	592.64	609.64	1202.28	422.75	449.14	435.73	-3.76	-11.1	-7.63
Average	175,445	169,873	345,319	254.43	323.71	578.14	617.97	786.25	1404.22	358.40	464.07	410.38	+8.28	+0.92	+3.91

Table 2 Age-specific incidence by sex, standardized to European and global populations.

Age	Specific incidence by BCC age (BCC/100,000 inhabitants per year)		Mean population treated at the health department of Hospital Dr. Peset (Valencia)		Standard European population		Incidence standardized in relation to the European population		Standard global population		Incidence standardized in relation to the world population	
	Total	Women	Men	Total	Men	Total	Total	Total	Total	Total	Total	
0-24	0	0	0	85,763	41,704	44,060	36,000	0	42840	0	0	
25-29	5.35	3.59	7.09	19,451	9657	9794	7000	0.37	7930	0.42	0.42	
30-34	11.43	20.30	2.82	24,278	11,965	12,314	7000	0.8	7610	0.87	0.87	
35-39	20.86	35.92	6.74	29,936	14,491	15,445	7000	1.46	7150	1.49	1.49	
40-44	68.05	86.26	50.94	29,063	14,079	14,984	7000	4.76	6590	4.48	4.48	
45-49	127.74	174.82	82.15	27,435	13,496	13,938	7000	8.94	6040	7.71	7.71	
50-54	146.60	215.20	77.65	25,088	12,576	12,512	7000	10.26	5370	7.87	7.87	
55-59	332.85	368.32	295.98	21,996	11,210	10,785	6000	19.97	4550	15.14	15.14	
60-64	646.78	626.10	669.14	18,884	9809	9075	5000	32.34	3720	24.05	24.05	
65-69	1053.69	842.61	1288.42	18,144	9554	8591	4000	42.15	2960	31.18	31.18	
70-74	1534.14	1170.42	1951.43	15,425	8241	7183	3000	46.02	2210	33.89	33.89	
75-79	2150.37	1353.67	3148.01	11,618	6459	5158	2000	43.01	1520	32.68	32.68	
80-84	2477.94	1653.51	3681.45	9830	5834	3996	1000	24.78	910	22.54	22.54	
85+	2211.25	1496.41	3662.12	8411	5635	2776	1000	22.11	630	13.93	13.93	
Total	410.38	358.40	464.07	345,322	174,710	170,611	100,000	256.98	100,030	196.26	196.26	

With the previous incidence estimates across all age ranges and the mentioned data on tumor multiplicity in a single patient, the lifetime risk of developing a BCC for our geographic area can also be estimated. Overall, the risk is 5.8% (5.02% for women and 7% for men).

## Discussion

We present an epidemiological study based on the retrospective review of health records from a health department in Valencia—both hospital and outpatient—to provide the most accurate approximation possible to the real incidence of basal cell carcinoma.

Although the study period (2010-2016) may seem distant from the present time, it is up-to-date compared to other Spanish studies,<sup>3,4,6,7</sup> and, as far as we know, it is the first one focused on Valencia and its metropolitan area.

The results obtained show a higher incidence than previously reported in other Spanish studies, and this incidence is clearly increasing.

Furthermore, the excess risk for men is similar to the 26% reported in former studies<sup>4</sup>, being closer to the 30% observed in our results.

Overall, our findings on the upward trend in incidence are consistent with other global studies—including Spanish studies—around a 6% annual increase, with a greater rise for women. Our data show more pronounced differences in trends by sex vs most previous studies.<sup>12</sup>

Since the incidence has been standardized to the European and global populations, a more realistic comparison with other regions and countries in our environment and worldwide can be made, positioning us at an intermediate point between countries with extreme risk, such as Australia, and those with low risk, such as Central African countries.

Additionally, the data obtained have allowed the calculation for the first time—something never done in the previously mentioned studies—of the lifetime risk (around 6%) of developing a BCC in a Spanish population.

Although having more up-to-date data would undoubtedly be optimal, the above-mentioned lack of specific records requires a thorough review of health records, a process that is time-consuming and delays results. It would be of great epidemiological interest to obtain successive data from our area in subsequent years and examine the variation during and after the COVID-19 pandemic.

On the other hand, our study has some limitations:

As stated, BCC cases without histological confirmation were accepted, so our incidence will be more realistic but inevitably higher than studies based solely on histological diagnoses.

Patient mobility between health departments, although likely balanced in its flows, prevents a completely precise estimate of the study population.

Similarly, it is impossible to quantify how many patients from our area are diagnosed and treated in private medicine, as we have no records on this topic. Some studies<sup>13</sup> suggest that up to 18.5% of malignant keratinocytic neoplasms—without differentiating among BCC, squamous cell carcinoma, and others—receive care outside the public system, which means that we might be underestimating this non-negligibly.

232 While the interannual variability of incidence—especially  
233 when broken down by sex—is noteworthy, the upward trend  
234 is unequivocal given the data over 7 consecutive years.

235 Finally, there is no comparative data with other regions of  
236 Spain in terms of phototypes, solar exposure, ethnicity, and  
237 other risk factors, so our conclusions might not be applicable  
238 to the entire national territory.

## 239 Conclusions

240 In conclusion, our study confirms that the incidence of basal  
241 cell carcinoma in the studied population is much higher than  
242 previously reported in other regions of Spain, thus providing  
243 more specific data—not previously available—for our geo-  
244 graphic area (Valencia). We have managed to estimate the  
245 lifetime risk of developing this tumor.

246 Moreover, by demonstrating an increasing incidence, the  
247 importance of conducting new epidemiological studies to  
248 update our knowledge and provide a more accurate perspec-  
249 tive on the disease seems obvious.

## 250 Funding

251 None declared.

## 252 Conflicts of interest

253 None declared.

## 254 References

- 255 1. Munyao TM, Othieno-Abinya NA. Cutaneous basal cell carcinoma  
256 in Kenya. *East Afr Med J.* 1999;76:97–100.
- 257 2. Richmond-Sinclair NM, Pandeya N, Ware RS, Neale RE, Williams  
258 GM, van der Pols JC, et al. Incidence of basal cell carcinoma  
259 multiplicity and detailed anatomic distribution: Longitudi-  
260 nal study of an Australian population. *J Invest Dermatol.*  
261 2009;129:323–8.
- 262 3. Revenga Arranz F, Paricio Rubio JF, Vazquez Salvado MM, del  
263 Villar Sordo V. Descriptive epidemiology of basal cell carcinoma  
264 and cutaneous squamous cell carcinoma in Soria (North-Eastern  
265 Spain) 1998-2000: A hospital-based survey. *J Eur Acad Dermatol  
Venereol.* 2004;18:137–41.

4. Vilar-Coromina N, Miró-Queralt J, Cano-Bautista A, Vilardell-Gil  
266 L, Torres Babié P, Marcos-Gragera R. Cáncer cutáneo distinto de  
267 melanoma: tendencia de la incidencia poblacional en Girona  
268 1994-2007. *Med Clin (Barc).* 2011;137:145–51, [http://dx.  
269 doi.org/10.1016/j.medcli.2011.03.023](http://dx.doi.org/10.1016/j.medcli.2011.03.023).
5. Miñano Medrano R, López Estebanz JL, Sanmartín-Jiménez  
270 O, Garcés JR, Rodríguez-Prieto MA, Vilarrasa-Rull E, et al., en  
271 nombre de REGESMOHS (Registro Español de Cirugía de Mohs).  
272 Risk of a second skin cancer in a cohort of patients with non-  
273 melanoma skin cancer -Basal cell carcinoma or squamous cell  
274 carcinoma-Treated with Mohs micrographic surgery: A national  
275 prospective cohort study. *Actas Dermosifiliogr.* 2022;113:451–8,  
276 <http://dx.doi.org/10.1016/j.ad.2022.01.003>. English, Spanish.
6. Bielsa I, Soria X, Esteve M, Ferrándiz C, Skin Cancer Study  
277 Group of Barcelonès Nord. Population-based incidence of basal  
278 cell carcinoma in a Spanish Mediterranean area. *Br J Derma-  
279 tol.* 2009;161:1341–6, [http://dx.doi.org/10.1111/j.1365-2133.  
280 2009.09468.x](http://dx.doi.org/10.1111/j.1365-2133.2009.09468.x).
7. Rubió-Casadevall J, Hernandez-Pujol AM, Ferreira-Santos MC,  
281 Morey-Esteve G, Vilardell L, Osca-Gelis G, et al. Trends in  
282 incidence and survival analysis in non-melanoma skin cancer  
283 from 1994 to 2012 in Girona. Spain: A population-based study.  
284 *Cancer Epidemiol.* 2016;45:6–10, [http://dx.doi.org/10.1016/  
285 j.canep.2016.09.001](http://dx.doi.org/10.1016/j.canep.2016.09.001).
8. Reiter O, Mimouni I, Gdalevich M, Marghoob AA, Levi A, Hodak E,  
286 et al., Leshem YA. The diagnostic accuracy of dermoscopy for  
287 basal cell carcinoma: A systematic review and meta-analysis.  
288 *J Am Acad Dermatol.* 2019;80:1380–8, [http://dx.doi.org/  
289 10.1016/j.jaad.2018.12.026](http://dx.doi.org/10.1016/j.jaad.2018.12.026).
9. «Memoria de Gestión 2016 - Conselleria de Sanitat Universal i  
290 Salut Públi-ca», s. f., Disponible en: [https://www.san.gva.es/  
291 documents/337726/3092526/memoria..2016.es.pdf/e16f353f-  
292 0c46-9560-4552-4b9717b70a32?t=1676970912013](https://www.san.gva.es/documents/337726/3092526/memoria..2016.es.pdf/e16f353f-0c46-9560-4552-4b9717b70a32?t=1676970912013)
10. Report of Eurostat's Task Force. Revision of the Standard Popu-  
293 lation. ISBN 978-92-79-31094-2 1977-0375. doi:10.2785/11470.  
294
11. Ahmad OB, Boschi Pinto C, Lopez AD, Murray CJL, Lozano R,  
295 Inoue M. Age standardization of rates: A new WHO standard.  
296 GPE Discussion Paper Series: No 31. 2001:10–2.  
297
12. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review  
298 of worldwide incidence of nonmelanoma skin cancer. *Br  
299 J Dermatol.* 2012;166:1069–80, [http://dx.doi.org/10.1111/  
300 j.1365-2133.2012.10830.x](http://dx.doi.org/10.1111/j.1365-2133.2012.10830.x).
13. Martín-Gorgojo A, Descalzo-Gallego MÁ, Arias-Santiago S,  
301 Molina-Leyva A, Gilaberte Y, Fernández-Crehuet P, et al. What  
302 proportion of the caseload at dermatology outpatient clinics  
303 in Spain do skin tumors account for? Results from the DIA-  
304 DERM national random sampling project. *Actas Dermosifiliogr  
305 (Engl Ed).* 2021;S0001-7310, [http://dx.doi.org/10.1016/j.ad.  
306 2021.02.004](http://dx.doi.org/10.1016/j.ad.2021.02.004). 00089-2. 307  
308  
309  
310  
311  
312  
313  
314